StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by Noloon Jun 10, 2019 1:00pm

92 Views

Post# 29812219

RE:RE:Great news!

Str8Shuter wrote:
Actually, it would work out to $507.5 million. However, that's just their goal. They "aim to deploy" 1.75 MM tests, which is great but of course we should expect many challenges along the way. Encouraging nevertheless!

507.5 is the potential total for Oncore if they reach 1.75 million tests. But GEN gets 10%, as stated in news. So, 50.75 ?

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario